
Company Overview
Company Type: Public Company
Website: www.amgen.com
Number of Employees: 25,200
Ticker: AMGN (NasdaqGS)
Year Founded: 1980


Business Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Financial Information (Currency: CAD, in mm) 
Total Revenue
36,517.0
Market Capitalization
195,050.8
TEV/Total Revenue
6.4x
EBITDA
18,906.9
Total Enterprise Value
232,548.6
TEV/EBITDA
12.0x
EBIT
14,038.4
Cash & ST Invst.
47,048.2
P/Diluted EPS Before Extra
17.9x
Net Income
10,961.2
Total Debt
84,546.1
Price/Tang BV
NM
Capital Expenditure
(1,531.7)
Total Assets
124,007.0
Total Debt/EBITDA
4.4x
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023


Estimates & Guidance Snapshot (Current Fiscal Year End: Dec-31-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Guidance Current FQ
Current FY
Guidance Current FY
NTM
EPS Normalized
6.43
-
25.11
24.45 - 25.83
25.91
Revenue (mm)
9,511.75
-
37,378.41
36,541.75 - 37,640.75
40,759.38
EBITDA (mm)
6,003.61
-
22,537.31
-
24,921.96

Forward Multiples (Current FY)

Price/Earnings
14.52x
TEV/REV
6.22x
TEV/EBITDA
10.32x
PEG
3.23x
P/BV
20.39x

Non-Periodic Estimates

Recommendation
Outperform (2.50)
Target Price
361.85
Potential Upside
(0.77)%
LT Growth (%)
4.50%
Guidance - LT Growth (%)
9.00% - 10.00%


Key Professionals
Name
Title
Bradway, Robert A.
Chairman, CEO & President
Griffith, Peter H.
Executive VP & CFO
Santos, Esteban 
Executive Vice President of Operations
Busch, Matthew C.
Chief Accounting Officer & VP of Finance
Zahigian, Mike 
Senior VP & Chief Information Officer
Sood, Arvind 
Vice President of Investor Relations
Graham, Jonathan P.
Executive VP, General Counsel & Secretary
Grygiel, Nancy A.
Senior VP of Worldwide Compliance & Business Ethics and Chief Compliance Officer
Miller, Derek 
Senior Vice President of Human Resources
Burton, Paul 
Senior VP & Chief Medical Officer
Deshaies, Raymond J.
Senior Vice President of Global Research
Elbonne, Jackie 
Senior VP of Quality & Chief Quality Officer

Key Board Members
Name
Title
Bradway, Robert A.
Chairman, CEO & President
Eckert, Robert A.
Lead Independent Director
Garland, Greg C.
Independent Director
Holley, Charles M.
Independent Director
Sugar, Ronald D.
Independent Director
Abreu, Maria T.
Member of Scientific Advisory Board of Inflammation
Austin, Wanda M.
Independent Director
Drake, Michael V.
Independent Director
Druker, Brian J.
Independent Director
Georgiou, George 
Member of Scientific Advisory Board of Research Trends & Emerging Technologies
Guttman-Yassky, Emma 
Member of Scientific Advisory Board of Inflammation
Han, Meilan 
Member of Scientific Advisory Board of Inflammation


Primary Industry Classification
Biotechnology


Primary Office Location
One Amgen Center Drive | Thousand Oaks, CA | 91320-1799 | United States
Phone: 805 447 1000   Fax: 805 447 1010

Current and Pending Investors
AJF Capital Management, Inc., Asset Management Company, Capital Research Global Investors, Elo Mutual Pension Insurance Company, Fidelity Investments, Fidelity Management & Research Company LLC, Keskinäinen työeläkevakuutusyhtiö Varma, Newground Social Investment, SPC, Omega Fund Management, LLC, Third Point LLC, Walden Asset Management

Prior Investors
3i Group plc (LSE:III), Alafi Capital Company LLC, Asset Management Associates 1989, L.P., Asset Management Ventures (Franklin Johnson), BB Biotech AG (SWX:BION), Bellevue Asset Management AG, Charles River Ventures, Inc., Court Square Capital Management, L.P., Domain Associates, L.L.C. (James Blair), Earlybird Venture Capital GmbH & Co. KG, EuclidSR Partners, International Biotechnology Trust plc (LSE:IBT), Mayfield Fund, L.L.C., PaineWebber Development Corporation, Painewebber R&D Partners L.P., SR One Capital Management, LP, SV Health Investors, LLC, USVP Management Company, LLC

Investment Arms
Amgen Retirement And Savings Plan, Amgen Ventures

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 364.04
Market Cap (mm)
195,050.8
Open
 365.68
Shares Out. (mm)
534.9
Previous Close
 364.65
Float %
99.8%
Change on Day
(0.60)
Shares Sold Short (mm)
6.3
Change % on Day
(0.2)%
Dividend Yield %
3.2%
Day High/Low
 368.05/ 360.66
Diluted EPS Excl. Extra Items
20.40
52 wk High/Low
 407.55/ 290.84
P/Diluted EPS Before Extra
17.82x
Volume (mm)
1.55
Avg 3M Dly Vlm (mm)
2.49
Beta 5Y
0.58


 
Delayed Quote** | Last Updated on Oct-05-2023 03:52 PM (GMT-5)
NasdaqGS:AMGN - Common Stock


Index Membership
Dow Jones Composite Average Index;Dow Jones Industrial Average;S&P 500;S&P 500 Health Care (Sector);S&P 100;S&P Composite 1500;S&P 500 Growth;S&P Global 1200;S&P 500 - Biotechnology (Sub Ind);S&P 500 - Biotechnology (Industry);S&P 500 - Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P 500 Equal Weighted;S&P 900 Pure Growth;S&P 900 Growth;S&P TMI Index;S&P Global 1200 Health Care Index;S&P 900;S&P 500 Pure Growth;S&P Biotechnology Select Industry Index;S&P Composite 1500 - Biotechnology (Industry);S&P Composite 1500 - Biotechnology (Sub Ind);S&P Composite 1500 - Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Composite 1500 Health Care (Sector);S&P Composite 1500 Growth;S&P Composite 1500 Pure Growth;S&P 500 EQUAL WEIGHTED Health Care (Sector);S&P 500 Ex-Financials, Real Estate, Utilities and Transportation Index;S&P 500 Dividend Index;S&P Americas BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Americas BMI Growth Index;S&P Americas BMI Value Index;S&P Americas BMI Index;S&P Americas BMI Health Care (Sector) Index;S&P Americas LargeMidCap Health Care (Sector) Index;S&P Developed BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Americas LargeMidCap Index;S&P Americas LargeMidCap Growth Index;S&P Americas LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Americas LargeMidCap Value Index;S&P Americas Over USD5 Billion Index;S&P Developed Ex-Asia-Pacific LargeMidCap Value Index;S&P Developed BMI Value Index;S&P Developed Ex-Asia-Pacific BMI Growth Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific BMI Value Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific LargeMidCap Health Care (Sector) Index;S&P Developed Ex-Europe BMI Growth Index;S&P Developed Ex-Europe BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Europe LargeMidCap Index;S&P Developed Ex-Europe LargeMidCap Growth Index;S&P DM Ex-Europe LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed BMI Index;S&P Developed Ex-Asia-Pacific BMI Growth Index;S&P Developed Ex-Asia-Pacific LargeMidCap Growth Index;S&P Developed Ex-Australia BMI Index;S&P Developed Ex-Australia LargeMidCap Health Care (Sector) Index;S&P Developed Ex-Eurozone BMI Growth Index;S&P Developed BMI Growth Index;S&P Developed Ex-Asia-Pacific BMI Index;S&P DM Ex-Asia-Pacific BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Asia-Pacific BMI Value Index;S&P Developed Ex-Australia LargeMidCap Index;S&P Developed Ex-Europe BMI Growth Health Care (Sector) Index;S&P Developed Ex-Australia LargeMidCap Value Health Care (Sector) Index;S&P Developed Ex-Canada BMI Index;S&P Developed Ex-Canada BMI Health Care (Sector) Index;S&P Developed Ex-Canada BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Canada LargeMidCap Growth Health Care (Sector) Index;S&P Developed Ex-Switzerland BMI Index;S&P Developed Ex-Switzerland LargeMidCap Health Care (Sector) Index;S&P Developed Ex-U.K. BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-U.K. LargeMidCap Health Care (Sector) Index;S&P DM Ex-U.K. LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Europe LargeMidCap Growth Health Care (Sector) Index;S&P Developed Ex-Eurozone BMI Index;S&P Developed Ex-Eurozone LargeMidCap Health Care (Sector) Index;S&P Developed Ex-Eurozone LargeMidCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Developed Ex-Eurozone LargeMidCap Value Health Care (Sector) Index;S&P Developed Ex-Japan BMI Index;S&P Developed Ex-Japan BMI Growth Health Care (Sector) Index;S&P Developed Ex-Japan BMI Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific LargeMidCap Index;S&P Developed Ex-Asia-Pacific LargeMidCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Developed Ex-Australia BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Australia LargeMidCap Growth Health Care (Sector) Index;S&P Developed Ex-Australia LargeMidCap Value Index;S&P Developed Ex-Japan LargeMidCap Growth Health Care (Sector) Index;S&P Developed Ex-Switzerland BMI Health Care (Sector) Index;S&P Developed Ex-Switzerland LargeMidCap Value Health Care (Sector) Index;S&P Developed Ex-Eurozone BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Eurozone LargeMidCap Growth Health Care (Sector) Index;S&P Developed Ex-Australia BMI Growth Index;S&P Developed Ex-Australia BMI Growth Health Care (Sector) Index;S&P Developed Ex-Australia BMI Health Care (Sector) Index;S&P Developed Ex-Canada BMI Growth Health Care (Sector) Index;S&P DM Ex-Canada LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Japan BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Switzerland LargeMidCap Index;S&P Developed Ex-Switzerland LargeMidCap Growth Health Care (Sector) Index;S&P Developed Ex-U.K. BMI Growth Health Care (Sector) Index;S&P Developed Ex-U.K. BMI Health Care (Sector) Index;S&P Developed Ex-Europe LargeMidCap Health Care (Sector) Index;S&P Developed Ex-Europe LargeMidCap Value Health Care (Sector) Index;S&P Developed Ex-Eurozone BMI Value Health Care (Sector) Index;S&P Developed Ex-Eurozone LargeMidCap Value Index;S&P Developed Ex-Eurozone Over USD5 Billion Index;S&P Developed Ex-Switzerland LargeMidCap Growth Index;S&P Developed Ex-Switzerland LargeMidCap Value Index;S&P Developed Ex-Canada BMI Growth Index;S&P Developed Ex-Canada BMI Value Health Care (Sector) Index;S&P Developed Ex-Europe BMI Index;S&P Developed Ex-U.K. BMI Value Health Care (Sector) Index;S&P Developed Ex-U.K. LargeMidCap Index;S&P Developed Ex-U.K. Over USD5 Billion Index;S&P Developed Ex-U.K. BMI Growth Index;S&P Developed Ex-U.K. BMI Value Index;S&P Developed Ex-U.K. LargeMidCap Growth Index;S&P Developed Ex-U.K. LargeMidCap Growth Health Care (Sector) Index;S&P Developed Ex-U.K. LargeMidCap Value Index;S&P Developed BMI Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific LargeMidCap Growth Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific LargeMidCap Value Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific Over USD5 Billion Index;S&P Developed Ex-Australia BMI Value Health Care (Sector) Index;S&P Developed Ex-Europe Over USD5 Billion Index;S&P Developed Ex-Eurozone BMI Growth Health Care (Sector) Index;S&P Developed Ex-Japan BMI Value Health Care (Sector) Index;S&P Developed Ex-Japan LargeMidCap Index;S&P Developed Ex-Australia Over USD5 Billion Index;S&P Developed Ex-Canada LargeMidCap Index;S&P Developed Ex-Canada LargeMidCap Value Health Care (Sector) Index;S&P Developed Ex-Canada Over USD5 Billion Index;S&P Developed Over USD5 Billion Index;S&P Global BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Pan Asia BMI Health Care (Sector) Index;S&P Global Ex-Pan Asia BMI Value Index;S&P Developed Ex-Europe BMI Value Index;S&P Developed Ex-Eurozone BMI Value Index;S&P Developed Ex-Eurozone LargeMidCap Index;S&P Developed Ex-Japan LargeMidCap Health Care (Sector) Index;S&P Developed Ex-Japan LargeMidCap Value Index;S&P Developed Ex-Switzerland BMI Growth Index;S&P Developed Ex-Switzerland BMI Growth Health Care (Sector) Index;S&P DM Ex-Switzerland BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Switzerland BMI Value Index;S&P Developed Ex-Switzerland LargeMidCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Developed LargeMidCap Index;S&P Developed LargeMidCap Growth Index;S&P Developed LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Switzerland Over USD5 Billion Index;S&P Developed BMI Growth Health Care (Sector) Index;S&P Developed Ex-Australia BMI Value Index;S&P Developed Ex-Canada BMI Value Index;S&P Developed Ex-Europe BMI Health Care (Sector) Index;S&P Developed Ex-Europe BMI Value Health Care (Sector) Index;S&P Developed Ex-Eurozone BMI Health Care (Sector) Index;S&P Developed Ex-Eurozone LargeMidCap Growth Index;S&P Developed Ex-Japan LargeMidCap Growth Index;S&P DM Ex-Japan LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Japan Over USD5 Billion Index;S&P Global Ex-Japan Over USD5 Billion Index;S&P Global Ex-Pan Asia BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Pan Asia LargeMidCap Growth Index;S&P Developed Ex-U.K. BMI Index;S&P Global Ex-Japan BMI Value Index;S&P Global BMI Index;S&P Global Ex-Japan BMI Health Care (Sector) Index;S&P Global Ex-Japan LargeMidCap Index;S&P Global Ex-Japan LargeMidCap Value Index;S&P Global Ex-Pan Asia LargeMidCap Value Index;S&P Global Ex-Pan Asia Over USD5 Billion Index;S&P North America BMI Value Health Care (Sector) Index;S&P North America LargeMidCap Growth Index;S&P North America LargeMidCap Value Health Care (Sector) Index;S&P North America Over USD5 Billion Index;S&P Global Ex-Pan Asia LargeMidCap Health Care (Sector) Index;S&P Global Over USD5 Billion Index;S&P North America BMI Index;S&P North America LargeMidCap Index;S&P North America LargeMidCap Growth Health Care (Sector) Index;S&P North America LargeMidCap Value Index;S&P Global Ex-Japan LargeMidCap Health Care (Sector) Index;S&P Global Ex-Japan LargeMidCap Pharmaceuticals, Biotech & Life Sciences (Industry Group) Index;S&P United States BMI Index;S&P Global LargeMidCap Health Care (Sector) Index;S&P United States BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P North America BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P North America BMI Value Index;S&P Global BMI Growth Index;S&P United States BMI Growth Health Care (Sector) Index;S&P United States BMI Health Care (Sector) Index;S&P United States LargeMidCap Value Health Care (Sector) Index;S&P United States BMI Value Health Care (Sector) Index;S&P United States LargeMidCap Growth Index;S&P United States LargeMidCap Growth Health Care (Sector) Index;S&P United States LargeMidCap Health Care (Sector) Index;S&P United States Over USD5 Billion Index;S&P Global Ex-Japan BMI Growth Index;S&P Global Ex-Japan BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Japan LargeMidCap Growth Index;S&P Global Ex-Pan Asia BMI Index;S&P Global Ex-Pan Asia BMI Growth Index;S&P Global Ex-Pan Asia LargeMidCap Index;S&P Global Ex-Pan Asia LargeMidCap Pharmaceuticals, Biotech & Life Sciences (Industry Group) Index;S&P Global LargeMidCap Index;S&P United States BMI Growth Index;S&P Global LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global LargeMidCap Value Index;S&P North America BMI Growth Index;S&P North America BMI Growth Health Care (Sector) Index;S&P North America BMI Health Care (Sector) Index;S&P North America LargeMidCap Health Care (Sector) Index;S&P North America LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P United States BMI Value Index;S&P Developed BMI Value Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific BMI Health Care (Sector) Index;S&P Developed Ex-Australia LargeMidCap Growth Index;S&P Developed Ex-Australia LargeMidCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Developed Ex-Canada LargeMidCap Growth Index;S&P Developed Ex-Canada LargeMidCap Health Care (Sector) Index;S&P Developed Ex-Canada LargeMidCap Value Index;S&P Developed Ex-Europe LargeMidCap Value Index;S&P Developed Ex-Japan BMI Growth Index;S&P Developed Ex-Japan BMI Value Index;S&P Developed Ex-Japan LargeMidCap Value Health Care (Sector) Index;S&P Developed Ex-Switzerland BMI Value Health Care (Sector) Index;S&P Developed Ex-U.K. LargeMidCap Value Health Care (Sector) Index;S&P Developed LargeMidCap Growth Health Care (Sector) Index;S&P Developed LargeMidCap Health Care (Sector) Index;S&P Developed LargeMidCap Value Index;S&P Developed LargeMidCap Value Health Care (Sector) Index;S&P Global BMI Health Care (Sector) Index;S&P Global BMI Value Index;S&P Global Ex-Japan BMI Index;S&P Global LargeMidCap Growth Index;S&P United States LargeMidCap Index;S&P United States LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P United States LargeMidCap Value Index;S&P 100 Equal Weight Price Return (USD) Index;S&P Developed Ex-Japan BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Eurozone BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P United States BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P North America BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Canada BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Asia Pacific BMI Growth Pharm, Biotech & Life Sciences (Industry Group) Index;S&P Developed Ex-Switzerland BMI Growth Pharm, Biotech & Life Sciences (Industry Group) Index;S&P Developed Ex-Europe BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-UK BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Australia BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Eurozone BMI Value Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Asia Pacific BMI Value Pharm, Biotech & Life Sciences (Industry Group) Index;S&P Developed Ex-Australia BMI Value Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Switzerland BMI Value Pharm, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-UK BMI Value Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Europe BMI Value Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Canada BMI Value Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P United States BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group)  Index;S&P North America BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Japan BMI Value Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P TMI Health Care;S&P Developed Ex-Israel BMI Growth Index;S&P Developed Ex-Israel BMI Growth Health Care (Sector) Index;S&P Developed Ex-Israel BMI Index;S&P Developed Ex-Israel BMI Health Care (Sector) Index;S&P Developed Ex-Israel BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Israel BMI Value Index;S&P Developed Ex-Israel BMI Value Health Care (Sector) Index;S&P Developed Ex-Israel LargeMidCap Growth Index;S&P Developed Ex-Israel LargeMidCap Growth Health Care (Sector) Index;S&P Developed Ex-Israel LargeMidCap Index;S&P Developed Ex-Israel LargeMidCap Health Care (Sector) Index;S&P DM Ex-Israel LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Israel LargeMidCap Value Index;S&P Developed Ex-Israel LargeMidCap Value Health Care (Sector) Index;S&P Developed Ex-Israel Over USD5 Billion Index;S&P Global 1200 - Biotechnology (Industry);S&P Global 1200 - Biotechnology (Sub Ind);S&P Global 1200 - Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Global Ex-Australia BMI Index;S&P Global Ex-Europe BMI Index;S&P Global Ex-United Kingdom BMI Index;S&P Developed Ex-Continental Europe BMI Index;S&P Developed Ex-Japan, Ex-South Korea BMI Index;S&P DM Ex.Japan LargeMidCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P DM Ex. Japan LargeMidCap Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Global Ex-Australia LargeMidCap;S&P Developed Ex-Japan & South Korea LargeMidCap;S&P 100 Health Care;S&P DM Ex-Canada LargeMidCap Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Eurozone LargeMidCap Value Pharmaceuticals, Biotechnology & Life Sciences (Subsecto;S&P DM Ex-Israel LargeMidCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group;S&P Developed Ex-Switzerland LargeMidCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Subs;S&P DM Ex-U.K. LargeMidCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Australia LargeMidCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Subsec;S&P Developed Ex-Asia-Pacific LargeMidCap Value Pharmaceuticals, Biotechnology & Life Sciences (Subs;S&P Developed Ex-Australia LargeMidCap Value Pharmaceuticals, Biotechnology & Life Sciences (Subsect;S&P DM Ex-Canada LargeMidCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group;S&P Developed Ex-Israel BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Israel BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Switzerland LargeMidCap Value Pharmaceuticals, Biotechnology & Life Sciences (Subse;S&P DM Ex-Europe LargeMidCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group;S&P DM Ex-Europe LargeMidCap Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Eurozone LargeMidCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Subsect;S&P Developed LargeMidCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed LargeMidCap Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Asia-Pacific LargeMidCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Sub;S&P United States LargeMidCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P DM Ex-U.K. LargeMidCap Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P DM Ex-Israel LargeMidCap Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P North America LargeMidCap Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P North America LargeMidCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P United States LargeMidCap Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);Dow Jones Industrial Average Equal Weight Index;S&P Global Ex-Australia & New Zealand LargeMidCap;S&P Global Ex-China A BMI;S&P Global Ex-China A LargeMidCap;S&P Developed Ex-Korea BMI;S&P 500 Low Volatility High Dividend Index;S&P Global Ex-Japan & China A LargeMidCap;S&P Developed Ex-Korea LargeMidCap;S&P Developed BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Asia Pacific BMI Val Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Switzerland BMI Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Australia LargeMidCap Val Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Canada BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Canada BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Australia BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Eurozone BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Europe BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Europe BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Eurozone LargeMidCap Val Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Switzerland LargeMidCap Val Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Europe LargeMidCap Val Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Eurozone BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Israel LargeMidCap Val Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Asia Pacific LargeMidCap Val Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Australia BMI Grwth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Switzerland LargeMidCap Grwth Pharma, Biotech & Life Sciences (Industry Group);S&P Developed Ex-Canada LargeMidCap Growth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Europe LargeMidCap Growth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-UK BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-UK LargeMidCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P North America BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-UK BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-UK LargeMidCap Val Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Japan BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Japan LargeMidCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Asia Pacific LargeMidCap Grwth Pharma, Biotech & Life Sciences (Industry Group);S&P United States BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Asia Pacific BMI Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Australia LargeMidCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Eurozone LargeMidCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Canada LargeMidCap Val Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Israel LargeMidCap Growth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Japan BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Japan LargeMidCap Val Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Switzerland BMI Val Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P United States BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P North America BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Korea BMI Growth;S&P Developed Ex-Korea BMI Value;S&P Developed Ex-Korea LargeMidCap Growth;S&P Developed Ex-Korea LargeMidCap Value;S&P Global 1200 Ex-Canada;S&P Developed Ex-Korea LargeMidCap Health Care (Sector) Index;"S&P Developed Ex-Korea LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group)


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP) (Pending)
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Europe
Biotechnology
3,644.00
9,299.00
2,726.00
ChemoCentryx, Inc.
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.ChemoCentryx, Inc. operates as a subsidiary of Amgen Inc.

United States and Canada
Biotechnology
37.00
419.00
73.00
TeneoBio, Inc.
TeneoBio, Inc., a biotechnology company, discovers and develops multi-specific biotherapeutic antibodies. Its products include UniAb, a human heavy-chain antibody to redirect the immune system to safely fight disease. The company also develops products for the treatment of multiple myeloma, b-cell cancers, prostate cancer, metabolic disorders, ovarian cancer, colon cancer, oncology, lymphoma tri-specific, gp120 (HIV) bispecific, and chronic viral infections. The company was incorporated in 2009 and is based in Newark, California. TeneoBio, Inc. operates as a subsidiary of Amgen Inc.

United States and Canada
Biotechnology
-
-
-
Rodeo Therapeutics Corporation
Rodeo Therapeutics Corporation develops small-molecule therapies to promote the regeneration and repair of tissues. It develops therapies for the treatment of inflammatory bowel disease and the promotion of blood cell reconstitution following bone marrow transplant. The company was incorporated in 2017 and is based in Seattle, Washington. As of April 28, 2021, Rodeo Therapeutics Corporation operates as a subsidiary of Amgen Inc.

United States and Canada
Biotechnology
-
-
-
Five Prime Therapeutics, Inc.
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of immuno-oncology and targeted cancer therapies. The company’s product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b to treat patients with gastric or gastroesophageal junction and GEJ cancer; FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28 that is in Phase Ia/1b clinical trial for patients with solid tumors; and BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase I/II clinical trial in combination with Opdivo in patients with advanced malignant tumors. Its preclinical programs include FPA157, an anti-CCR8 antibody that is engineered to eliminate CCR8-expressing CD4+ regulatory T cells within solid tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, and BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California. As of April 16, 2021, Five Prime Therapeutics, Inc. operates as a subsidiary of Amgen Inc.

United States and Canada
Biotechnology
13.00
332.00
47.00
Amgen K.K.
Amgen K.K. develops, manufactures, and sells pharmaceutical products. The company was founded in 2013 and is based in Chiyoda, Japan. Amgen K.K. was formerly known as Amgen Astellas Biopharma K.K.. As a result of acquisition of Amgen Astellas Biopharma K.K..by Amgen Inc., Amgen Astellas Biopharma K.K.'s name was changed. Amgen K.K. operates as a subsidiary of Amgen Inc.

Asia / Pacific
Pharmaceuticals
-
-
-
Worldwide Rights to Otezla of Celgene Corporation
As of November 20, 2019, Worldwide Rights to Otezla of Celgene Corporation was acquired by Amgen Inc. Worldwide Rights to Otezla of Celgene Corporation comprises manufacturing of oral and non-biologic treatment for psoriasis and psoriatic arthritis medicine business. The asset is located in the United States.

United States and Canada
Biotechnology
-
-
-

Investments as an LP
Andera Partners, Ariel Alternatives, LLC, BioDiscovery 2, BioDiscovery 3, FCPR, CW Group, Inc., CW Ventures III, L.P., Oxford Bioscience Partners, Project Black, LP, Société Générale Gestion, Specialized European Fund for Therapeutic Innovation, FCPR, venBio Global Strategic Fund II L.P., VenBio Global Strategic Fund, L.P., venBio LLC


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Feb-14-2023
Feb-15-2023
Public Offering
Target
Amgen Inc. (NasdaqGS:AMGN)


4,243.88
Feb-14-2023
Feb-15-2023
Public Offering
Target
Amgen Inc. (NasdaqGS:AMGN)


4,236.61
Feb-14-2023
Feb-15-2023
Public Offering
Target
Amgen Inc. (NasdaqGS:AMGN)


3,743.48
Feb-14-2023
Feb-15-2023
Public Offering
Target
Amgen Inc. (NasdaqGS:AMGN)


2,743.65
Feb-14-2023
Feb-15-2023
Public Offering
Target
Amgen Inc. (NasdaqGS:AMGN)


2,734.63
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Oct-02-2023
Company Conference Presentations
Amgen Inc. Presents at Formulation & Delivery US 2023, Oct-02-2023
Sep-26-2023
Company Conference Presentations
Amgen Inc. Presents at Generis American Medical Device (AMD) Summit, Sep-26-2023
Sep-20-2023
Company Conference Presentations
Amgen Inc. Presents at Heartland Summit, Sep-20-2023 09:30 AM
Sep-20-2023
Company Conference Presentations
Amgen Inc. Presents at 13th annual DPHARM: Disruptive Innovations, Sep-20-2023
Sep-19-2023
Company Conference Presentations
Amgen Inc. Presents at Longwood Healthcare Leaders Conference 2023, Sep-19-2023 02:00 PM

Competitors
3M Company (NYSE:MMM), Abbott Laboratories (NYSE:ABT), AbbVie Inc. (NYSE:ABBV), Acasti Pharma Inc. (NasdaqCM:ACST), Accord Healthcare, Inc., Acusphere, Inc. (OTCPK:ACUS), ADVANZ PHARMA Corp. Limited, Aegerion Pharmaceuticals, Inc., Akebia Therapeutics, Inc. (NasdaqCM:AKBA), Akzo Nobel N.V. (ENXTAM:AKZA), Alkeus Pharmaceuticals, Inc., Allergan Finance, LLC, Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), Alvogen, Inc., AMAG Pharmaceuticals, Inc., Amarin Corporation plc (NasdaqGM:AMRN), American Regent, Inc., Amryt Pharma plc, Arkema Inc., Asahi Kasei Medical Co., Ltd., Asahi Kasei Pharma Corporation, Astellas Pharma Inc. (TSE:4503), Astex Pharmaceuticals, Inc., AstraZeneca PLC (LSE:AZN), Aurobindo Pharma Limited (NSEI:AUROPHARMA), B. Braun Melsungen AG, B. Braun Se, Bain Medical Equipment (Guangzhou) Co., Ltd., BASF Corporation, BASF SE (XTRA:BAS), Baxalta Incorporated, Bayer Aktiengesellschaft (XTRA:BAYN), Becton, Dickinson and Company (NYSE:BDX), Biogen Inc. (NasdaqGS:BIIB), BiPar Sciences, Inc., bluebird bio, Inc. (NasdaqGS:BLUE), Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company (NYSE:BMY), Cardax, Inc. (OTCPK:CDXI), Cefaly Technology, Celanese Corporation (NYSE:CE), Celgene Corporation, Cephalon, Inc., ChemoCentryx, Inc., Chiron, Corp. (Acquired), Clariant AG (SWX:CLN), Coherus BioSciences, Inc. (NasdaqGM:CHRS), Croda International Plc (LSE:CRDA), CTI BioPharma Corp., Cullinan Oncology, Inc. (NasdaqGS:CGEM), Daiichi Sankyo Company, Limited (TSE:4568), Danaher Corporation (NYSE:DHR), Diocle S.p.A., Dova Pharmaceuticals, Inc., Dr. Reddy's Laboratories Limited (BSE:500124), EA Pharma Co., Ltd, Eisai Co., Ltd. (TSE:4523), electroCore, Inc. (NasdaqCM:ECOR), Eli Lilly and Company (NYSE:LLY), EMD Millipore Corporation, Endo International plc (OTCPK:ENDP.Q), eNeura Inc., EVER Neuro Pharma GmbH, Fresenius Medical Care AG & Co. KGaA (XTRA:FME), Fuso Pharmaceutical Industries,Ltd. (TSE:4538), Galapagos NV (ENXTAM:GLPG), GE Healthcare Limited, Genentech, Inc., Genmab A/S (CPSE:GMAB), Genzyme Corporation Inc, Gilead Sciences, Inc. (NasdaqGS:GILD), Glenmark Life Sciences Limited (NSEI:GLS), GSK plc (LSE:GSK), H. Lundbeck A/S (CPSE:HLUN A), Hoffmann-La Roche Inc., Humira S.R.O., ICOS Corporation, Illumina, Inc. (NasdaqGS:ILMN), Immunex Corporation, Incyte Corporation (NasdaqGS:INCY), Intellipharmaceutics International Inc. (TSX:IPCI), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), ISP Capital Co., Ltd., Janssen Biotech, Inc., Janssen Pharmaceutical K.K., Janssen Research & Development, LLC, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Johnson & Johnson (NYSE:JNJ), Johnson & Johnson LLC, K+S Aktiengesellschaft (XTRA:SDF), Karyopharm Therapeutics Inc. (NasdaqGS:KPTI), Kastle Therapeutics, LLC, Kawasumi Laboratories, Incorporated, Kubota Pharmaceutical Holdings Co., Ltd. (TSE:4596), LANXESS Corporation, LES LABORATOIRES SERVIER, SAS, Lumara Health, Inc., Mallinckrodt plc (OTCPK:MNKT.Q), Matinas BioPharma Holdings, Inc. (NYSEAM:MTNB), Medtronic plc (NYSE:MDT), Merck & Co., Inc. (NYSE:MRK), Merck (Schweiz) AG, Merck KGaA (XTRA:MRK), Merck Sharp & Dohme LLC, Millennium Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma Corporation, Moderna, Inc. (NasdaqGS:MRNA), Mylan Institutional Inc., Mylan Pharmaceuticals Inc., Mylan, Inc., Nautilus Biotech S.A., Nikkiso Co., Ltd. (TSE:6376), Nipro Corporation (TSE:8086), Novartis AG (SWX:NOVN), Novartis International AG, Novo Nordisk A/S (CPSE:NOVO B), Nutra Pharma Corp. (OTCPK:NPHC), Oncopeptides AB (publ) (OM:ONCO), Ono Pharmaceutical Co., Ltd. (TSE:4528), Organon Pharmaceuticals USA, Inc., OSI Pharmaceuticals Inc. (Out of Business), Otsuka America Pharmaceutical, Inc, Outset Medical, Inc. (NasdaqGS:OM), Perrigo Company plc (NYSE:PRGO), Pfizer Inc. (NYSE:PFE), Pfizer Limited (NSEI:PFIZER), Pharmion LLC, Physidia SA, Piramal Enterprises Limited (BSE:500302), Poniard Pharmaceuticals, Inc. (OTCPK:PARD), Precigen, Inc. (NasdaqGS:PGEN), Quanta Dialysis Technologies Limited, Radius Health, Inc., Rain Oncology Inc. (NasdaqGS:RAIN), Reata Pharmaceuticals, Inc., ReceptoPharm, Inc., Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Rhodia S.A., Rigel Pharmaceuticals, Inc. (NasdaqGS:RIGL), Roche Holding AG (SWX:ROG), Roche Holdings, Inc., Rockwell Medical, Inc. (NasdaqCM:RMTI), Sandoz GmbH, Sandoz International GmbH, Sanofi (ENXTPA:SAN), Sanofi India Limited (BSE:500674), Sanofi SA, Sanofi-Aventis A.E.B.E., Sanofi-Aventis U.S. LLC, SB-Kawasumi Laboratories Inc, Seagen Inc. (NasdaqGS:SGEN), Shandong Weigao Group Medical Polymer Company Limited (SEHK:1066), Shire plc, Solvay SA (ENXTBR:SOLB), Spectrum Pharmaceuticals, Inc., Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA), Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited (TSE:4502), Terumo Corporation (TSE:4543), Teva Pharmaceutical Industries Ltd., Portfolio Of Generic Pharmaceutical Products (Acquired), The Medicines Company, Theranica Bio-Electronics Ltd., Toray Industries, Inc. (TSE:3402), UCB Pharma S.A., Ucb S.A., United Therapeutics Corporation (NasdaqGS:UTHR), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), VIVUS, Inc., Wacker Chemie AG (XTRA:WCH), Wyeth LLC, Wyeth Pharmaceuticals LLC, Zoetis Inc. (NYSE:ZTS)

M&A Advisors
Bear Stearns Companies LLC, Citigroup CIB, Citigroup Global Markets Inc., Clifford Chance Partnerschaftsgesellschaft, Covington & Burling LLP, De Brauw Blackstone Westbroek N.V., DLA Piper LLP (US), Ernst & Young LLP, Goldman Sachs & Co. LLC, Gordon Dyal & Co. Advisory Group LP, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, Hogan Lovells US LLP, Latham & Watkins LLP, Lazard Freres & Co. LLC, Mannheimer Swartling Advokatbyrå Aktiebolag, Merrill Lynch, Pierce, Fenner & Smith Incorporated, Moelis Asset Management LP, Morgan Stanley & Co. LLC, Morgan Stanley (NYSE:MS), Paul Hastings LLP, PJT Partners (UK) Limited, PJT Partners Inc. (NYSE:PJT), PJT Partners LP, Richards, Layton & Finger, P.A., Skandinaviska Enskilda Banken AB (publ) (OM:SEB A), Sullivan & Cromwell LLP, The Goldman Sachs Group, Inc. (NYSE:GS), Wachtell, Lipton, Rosen & Katz LLP, William Fry, Solicitors


Advisors
Most Recent Auditor
Ernst & Young LLP
M&A Advisors
Bear Stearns Companies LLC, Citigroup CIB, Citigroup Global Markets Inc., Clifford Chance Partnerschaftsgesellschaft, Covington & Burling LLP, De Brauw Blackstone Westbroek N.V., DLA Piper LLP (US), Ernst & Young LLP, Goldman Sachs & Co. LLC, Gordon Dyal & Co. Advisory Group LP, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, Hogan Lovells US LLP, Latham & Watkins LLP, Lazard Freres & Co. LLC, Mannheimer Swartling Advokatbyrå Aktiebolag, Merrill Lynch, Pierce, Fenner & Smith Incorporated, Moelis Asset Management LP, Morgan Stanley & Co. LLC, Morgan Stanley (NYSE:MS), Paul Hastings LLP, PJT Partners (UK) Limited, PJT Partners Inc. (NYSE:PJT), PJT Partners LP, Richards, Layton & Finger, P.A., Skandinaviska Enskilda Banken AB (publ) (OM:SEB A), Sullivan & Cromwell LLP, The Goldman Sachs Group, Inc. (NYSE:GS), Wachtell, Lipton, Rosen & Katz LLP, William Fry, Solicitors
Private Placement Advisors
Latham & Watkins LLP, The Goldman Sachs Group, Inc. (NYSE:GS)
Public Offering Advisors
Ernst & Young LLP, Latham & Watkins LLP, Latham & Watkins LLP, Shearman & Sterling LLP


Most Recent Auditor
Ernst & Young LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

03:05 AM
AMGN
Amgen Inc 2023_10_05
Reports
15
William Blair & Company L.L.C.
Phipps, Matthew Christopher
Oct 03, 2023 10:19 AM
AMGN
FDA Briefing Documents Shine a Light on Multiple Sources of Bias and Question CB200's Reliability as a Well-Controlled Trial
Reports
7
William Blair & Company L.L.C.
Phipps, Matthew Christopher
Oct 03, 2023 04:58 AM
AMGN
Molecular Targets and Cancer Therapeutics Conference Planner and a Few Highlighted Presentations
Reports
17
ValuEngine, Inc.

Oct 02, 2023 02:46 AM
AMGN
ValuEngine Rating and Forecast Report for AMGN
Reports
11
The Economy Matters

Oct 02, 2023 01:43 AM
AMGN
The Economy Matters
Reports
8
CFRA Equity Research
Hardy, Sel
Sep 30, 2023 03:56 PM
AMGN
Amgen Inc.
Reports
9
New Constructs, LLC

Sep 29, 2023 08:07 PM
AMGN
AMGN: Forensic Stock Earnings & Valuation
Reports
6
Barclays
Gould, Carter Lewis
Sep 27, 2023 07:57 PM
AMGN
Amgen Inc.: UPDATE: EADV Abstracts Suggests Narrow Edge for Rocatinlimab
Reports
8
William Blair & Company L.L.C.
Phipps, Matthew Christopher
Sep 27, 2023 01:37 PM
AMGN
LBAs for ESMO: The Long-Awaited MARIPOSA, Plus CodeBreak 300, DeLLphi-301, CM901/77T, PSMAfore, and mRNA-4157 Updates
Reports
7
MarketLine

Sep 27, 2023 06:01 AM
AMGN
Amgen, Inc.
Reports
72


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


The Vanguard Group, Inc.

48,870,345

9.14

17,543.1

Jun-30-2023


BlackRock, Inc.

46,954,053

8.78

16,855.2

Jun-30-2023


State Street Global Advisors, Inc.

29,098,881

5.44

10,445.7

Jun-30-2023


PRIMECAP Management Company

14,736,435

2.75

5,290.0

Jun-30-2023


Geode Capital Management, LLC

11,799,183

2.21

4,235.6

Jun-30-2023


Charles Schwab Investment Management, Inc.

11,243,401

2.10

4,036.1

Jun-30-2023


Capital Research and Management Company

10,148,256

1.90

3,642.9

Jun-30-2023


Morgan Stanley, Investment Banking and Brokerage Investments

9,715,043

1.82

3,487.4

Jun-30-2023


Wells Fargo & Company, Securities and Brokerage Investments

7,292,626

1.36

2,617.9

Jun-30-2023


Northern Trust Global Investments

6,722,162

1.26

2,413.1

Jun-30-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Franklin Resources, Inc.
3,158,473
1,094,175
T. Rowe Price Group, Inc.
4,840,989
1,018,577
Morgan Stanley, Investment Banking and Brokerage Investments
9,715,043
799,398
Federated Hermes, Inc.
2,248,464
763,169
Montrusco Bolton Investments Inc.
1,418,519
623,118

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Capital Research and Management Company
10,148,256
(2,258,209)
BlackRock, Inc.
46,954,053
(1,826,180)
JP Morgan Asset Management
3,252,854
(1,441,469)
FMR LLC
3,201,340
(1,397,740)
Renaissance Technologies LLC
261,345
(861,300)


S&P Global Ratings Credit Ratings
Debt Type (Rating Type)
Current Rating
Rating Date
Current CreditWatch / Outlook
Current CreditWatch / Outlook Date
Issuer Credit Rating (Local Currency LT)
BBB+
Dec-12-2022
Negative
12/12/2022 10:27:10 AM
Issuer Credit Rating (Local Currency ST)
A-2
Nov-21-2019
NM
11/21/2019 12:52:49 PM
Issuer Credit Rating (Foreign Currency LT)
BBB+
Dec-12-2022
Negative
12/12/2022 10:27:10 AM
Issuer Credit Rating (Foreign Currency ST)
A-2
Nov-21-2019
NM
11/21/2019 12:52:49 PM


News Headlines
Date/Time
Headline
Source
Sep-15
Generate Biomedicines Raises USD273 Million in Series C Financing
Marketline - Deals
Sep-13
Nutriband Inc. Receives Five Nominations in the Pharma Industry Awards 2023
ENP Newswire
Sep-12
US Neumora Therapeutics launches IPO
SeeNews Deals
Sep-12
Cross-border deal is the only $10B-plus M&A transaction announced in August
S&P Global Market Intelligence
Sep-11
AMGEN PRESENTS NEW LUMAKRAS PLUS CHEMOTHERAPY DATA IN FIRST-LINE KRAS G12C NSCLC AT WCLC
ENP Newswire


Company Coverage
This company is not on any Coverage List.

Products
ABP 654 (Future), ABP 938 (Future), ABP 959 (Future), Aimovig, AMG 108 (Future), AMG 110 (Future), AMG 119 (Future), AMG 131, AMG 133 (Future), AMG 139, AMG 151, AMG 160, AMG 167, AMG 171 (Future), AMG 172 (Future), AMG 176 (Future), AMG 181 (Future), AMG 199 (Future), AMG 208 (Future), AMG 211 (Future), AMG 212 (Future), AMG 221 (Future), AMG 222 (Future), AMG 223 (Future), AMG 224 (Future), AMG 228 (Future), AMG 232 (Future), AMG 256 (Future), AMG 282 (Future), AMG 301 (Future), AMG 317 (Future), AMG 319 (Future), AMG 330 (Future), AMG 333 (Future), AMG 337 (Future), AMG 357 (Future), AMG 386, AMG 397 (Future), AMG 404 (Future), AMG 420 (Future), AMG 424 (Future), AMG 430 (Future), AMG 479 (Future), AMG 506 (Future), AMG 509 (Future), AMG 520 / CNP520, AMG 557 (Future), AMG 562 (Future), AMG 581 (Future), AMG 594 (Future), AMG 595 (Future), AMG 596 (Future), AMG 598 (Future), AMG 634 (Future), AMG 650, AMG 673 (Future), AMG 701, AMG 714, AMG 729 (Future), AMG 757, AMG 761 (Future), AMG 780 (Future), AMG 811 (Future), AMG 820 (Future), AMG 853 (Future), AMG 876 (Future), AMG 899, AMG 900 (Future), AMG 910 (Future), AMG 966 (Future), AMG 986 (Future), AMGEVITA, AMJEVITA, Aranesp, AutoTouch, AVSOLA, Blinatumomab, BLINCYTO, CE-IVD CRC RAScan Kits (Future), Cetuximab (Future), Conatumumab (Future), Corlanor, Dulanermin (Future), Efavaleukin Alfa, Emirodatamab (Future), Enbrel, ENBREL Mini, EPOGEN, EVENITY, Extended RAS Panel, GAUSS-2 (Future), GAUSS-3 (Future), hyper-CVAD + Blinatumomab + Inotuzumab Ozogamicin (Future), IMLYGIC, Ipilimumab-Nivolumab-Denosumab (Future), KANJINTI, Kepivance (Future), Kinase Inhibitor, KYPROLIS, KYPROLIS + Dexamethasone + DARZALEX, LAPLACE-2 (Future), Licensing of Nexavar, LUMAKRAS, Mini-hyper-CVD + Inotuzumab Ozogamicin (Future), Motesanib (Future), Multigene (Future), MVASI, Neulasta, Neulasta Onpro Kit, NEUPOGEN, Nexavar, Nplate, Olpasiran (Future), Omecamtiv Mecarbil (Future), Oprozomib (Future), Otezla, Parsabiv, Pasotuxizumab (Future), Ponatinib + Blinatumomab (Future), Prefilled SureClick Auto Injector, Prolia, Repatha, RIABNI, Rocatinlimab (Future), Rozibafusp Alfa, RUTHERFORD-2 (Future), Sensipar/Mimpara, Sotorasib (Future), Stemgen, SureClick (Future), TAVNEOS, Tezepelumab, Tezspire, Trebananib (Future), Vectibix, Velcade (Future), XGEVA, XmAb5871 (Future)


Upcoming Events
Date/Time
Type
Oct-12-2023
Company Conference Presentations
Oct-12-2023
Conferences
Oct-15-2023
Conferences
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
5:43 AM
Oct-05-2023
Amgen Inc. (NasdaqGS:AMGN)
SEC
8-K (8.01)
176 KB
Sep-12-2023
Sep-11-2023
Amgen Inc. (NasdaqGS:AMGN)
SEC
8-K (8.01)
176 KB
Sep-05-2023
Sep-01-2023
Amgen Inc. (NasdaqGS:AMGN)
SEC
8-K (8.01)
178 KB
Sep-01-2023
Sep-01-2023
Amgen Inc. (NasdaqGS:AMGN)
SEC
8-K (7.01, 8.01, 9.01)
227 KB
Aug-04-2023
Aug-01-2023
Amgen Inc. (NasdaqGS:AMGN)
SEC
8-K (5.02)
143 KB
Aug-04-2023
Jun-30-2023
Amgen Inc. (NasdaqGS:AMGN)
SEC
10-Q
10 MB
Aug-03-2023
Aug-03-2023
Amgen Inc. (NasdaqGS:AMGN)
SEC
8-K (2.02, 9.01)
830 KB
Jun-15-2023
Dec-31-2022
Amgen Inc. (NasdaqGS:AMGN)
SEC
11-K
607 KB
Jun-15-2023
Dec-31-2022
Amgen Inc. (NasdaqGS:AMGN)
SEC
11-K
568 KB
Jun-05-2023
Jun-02-2023
Amgen Inc. (NasdaqGS:AMGN)
SEC
8-K (8.01)
190 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Gordon, Murdo  (Executive VP of Global Commercial Operations)
Aug-10-2023
Common Stock
(9,558)
(3,445,785)
Open Market Disposition
(23.38)
Form 4
Holley Jr., Charles M. (Independent Director)
Aug-08-2023
Restricted Stock Units
153
0
Other Acquisition
1.92
Form 4
Drake M.D., Michael V. (Independent Director)
Aug-08-2023
deferred Stock
124
0
Other Acquisition
6.56
Form 4
Ishrak, S. Omar (Independent Director)
Aug-08-2023
Restricted Stock Units
124
0
Other Acquisition
5.05
Form 4
Grygiel, Nancy A. (Senior VP of Worldwide Compliance & Business Ethics and Chief Compliance Officer)
Jul-31-2023
Common Stock
(1,129)
(366,601)
Sale to Issuer
(7.88)
Form 4
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Bradway, Robert A.
Chairman, CEO & President
805 447 1000
(805) 499-6751

Eckert, Robert A.
Lead Independent Director
805 447 1000
805 447 1010

Garland, Greg C.
Independent Director
805 447 1000
805 447 1010

Holley, Charles M.
Independent Director
805 447 1000
805 447 1010

Sugar, Ronald D.
Independent Director
805 447 1000
805 447 1010

Abreu, Maria T.
Member of Scientific Advisory Board of Inflammation
805 447 1000
805 447 1010

Austin, Wanda M.
Independent Director
805 447 1000
805 447 1010

Drake, Michael V.
Independent Director
805 447 1000
805 447 1010

Druker, Brian J.
Independent Director
805 447 1000
805 447 1010

Georgiou, George 
Member of Scientific Advisory Board of Research Trends & Emerging Technologies
805 447 1000
805 447 1010

Guttman-Yassky, Emma 
Member of Scientific Advisory Board of Inflammation
805 447 1000
805 447 1010

Han, Meilan 
Member of Scientific Advisory Board of Inflammation
805 447 1000
805 447 1010

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Bradway, Robert A.
Chairman, CEO & President
805 447 1000
(805) 499-6751

Griffith, Peter H.
Executive VP & CFO
805 447 1000
805 447 1010

Santos, Esteban 
Executive Vice President of Operations
805 447 1000
805 447 1010

Busch, Matthew C.
Chief Accounting Officer & VP of Finance
805 447 1000
805 447 1010

Zahigian, Mike 
Senior VP & Chief Information Officer
805 447 1000
805 447 1010
-
Sood, Arvind 
Vice President of Investor Relations
(805) 447-1060
805 447 1010
arvinds@amgen.com
Graham, Jonathan P.
Executive VP, General Counsel & Secretary
805 447 1000
805 447 1010

Grygiel, Nancy A.
Senior VP of Worldwide Compliance & Business Ethics and Chief Compliance Officer
805 447 1000
805 447 1010

Miller, Derek 
Senior Vice President of Human Resources
805 447 1000
805 447 1010

Burton, Paul 
Senior VP & Chief Medical Officer
805 447 1000
805 447 1010

Deshaies, Raymond J.
Senior Vice President of Global Research
805 447 1000
805 447 1010

Elbonne, Jackie 
Senior VP of Quality & Chief Quality Officer
805 447 1000
805 447 1010

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
